ResearcherUniversity of MichiganNo recent work listed
Daniel M. Kremer
Matched on ORCID iD 0000-0001-6224-0550; OpenAlex author ID A5063994400. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 28
2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers
Papers 4
- GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. Co-author DOI 10.1038/s41467-021-24859-2↗
- Hyaluronic acid fuels pancreatic cancer cell growth. Co-author DOI 10.7554/elife.62645↗
- Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. Co-author DOI 10.1016/j.cmet.2019.02.001↗
- Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci.insight.97422↗
Closest collaborators
The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christopher J. Halbrook · 4 shared papers, 2018–2021 · strength 0.32
- Paper Hyaluronic acid fuels pancreatic cancer cell growth. DOI 10.7554/elife.62645↗
- Paper GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. DOI 10.1038/s41467-021-24859-2↗
- Paper Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. DOI 10.1016/j.cmet.2019.02.001↗
- Costas Andreas Lyssiotis · 4 shared papers, 2018–2021 · strength 0.32
- Paper Hyaluronic acid fuels pancreatic cancer cell growth. DOI 10.7554/elife.62645↗
- Paper GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. DOI 10.1038/s41467-021-24859-2↗
- Paper Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. DOI 10.1016/j.cmet.2019.02.001↗
- Marina Pasca di Magliano · 3 shared papers, 2018–2021 · strength 0.22
- Paper GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. DOI 10.1038/s41467-021-24859-2↗
- Paper Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. DOI 10.1016/j.cmet.2019.02.001↗
- Paper Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. DOI 10.1172/jci.insight.97422↗
- Samuel Andrew Kerk · 2 shared papers, 2021 · strength 0.19
- Howard C. Crawford · 2 shared papers, 2019–2021 · strength 0.16
- Jennifer P. Morton · 2 shared papers, 2018–2019 · strength 0.13
- Kayvan R. Keshari · 1 shared paper, 2021 · strength 0.10
- Haoqiang Ying · 1 shared paper, 2021 · strength 0.10
- Peter Kim · 1 shared paper, 2021 · strength 0.10
- Megan D. Radyk · 1 shared paper, 2021 · strength 0.10
- Mengrou Shan · 1 shared paper, 2021 · strength 0.09
- Zeribe C. Nwosu · 1 shared paper, 2021 · strength 0.09
- Eileen S. Carpenter · 1 shared paper, 2021 · strength 0.09
- Michael A. Badgley · 1 shared paper, 2021 · strength 0.09
- Kenneth P. Olive · 1 shared paper, 2021 · strength 0.09
- Samantha B. Kemp · 1 shared paper, 2019 · strength 0.07
- Stephan B. Dreyer · 1 shared paper, 2019 · strength 0.07
- Yaqing Zhang · 1 shared paper, 2019 · strength 0.07
- Corbin Pontious · 1 shared paper, 2019 · strength 0.07
- Jiaqi Shi · 1 shared paper, 2019 · strength 0.07
- Timothy L. Frankel · 1 shared paper, 2019 · strength 0.07
- David Kuang-Fu Chang · 1 shared paper, 2019 · strength 0.07
- Li Zhang · 1 shared paper, 2019 · strength 0.07
- Andrew Victor Biankin · 1 shared paper, 2019 · strength 0.07
- Mats E. Ljungman · 1 shared paper, 2018 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.